Esketamine nasal spray (Spravato) is one of several routes by which ketamine reaches the bloodstream, and the choice of route changes far more than convenience. It affects bioavailability, the predictability of the dose, the speed of onset, the monitoring required, the setting in which it can legally and safely be given and, ultimately, the cost. A typical session runs about 120 minutes of administration, with a usual cost somewhere between 600 and 900 dollars per session in the United States. Often partially covered, subject to prior authorisation and documented failure of prior antidepressants.
The relevant question about a provider is not only whether they are licensed but whether their training covers both the psychiatric assessment and the physiological monitoring. Read against the United States market, dosing for mood indications sits far below anaesthetic levels, typically calculated near 0.5 milligrams per kilogram of body weight and delivered slowly across about forty minutes. For anyone weighing options in the United States, using remote care to mail a dissociative anaesthetic to an unmonitored patient is a different proposition from using it for the consultation, and the distinction is worth insisting on. A clinic willing to escalate frequency on request, or to supply product without meaningful assessment, has removed the safeguards that keep the risk manageable. Dissociation is the effect people ask about most: a sense of distance from the body, altered time perception and sometimes visual distortion, typically peaking partway through and resolving within half an hour of the infusion ending.
How Esketamine nasal spray (Spravato) works in practice
A dose calculated against body weight and adjusted across a course reflects a different philosophy from one held constant regardless of what the previous session produced. A programme should be able to say plainly who is in the building during a session, what their credential is, and what the plan is if a person becomes acutely distressed. Ketamine acts on the glutamate system rather than the monoamine pathways targeted by conventional antidepressants, which is the likely reason its timeline differs so sharply. Nothing about the United States changes that. Transient elevation in blood pressure and heart rate is expected, which is the reason monitoring runs continuously rather than at intervals.
The setting is not incidental decoration. Trial protocols were run in monitored medical environments, and the structural elements of those environments are part of what makes the treatment defensible: a clinician credentialed to manage sedation present in the building, continuous monitoring of blood pressure, heart rate and oxygen saturation, resuscitation equipment available, and a defined plan for what happens if someone becomes acutely distressed. A comfortable recliner and dim lighting are pleasant. They are not a substitute for any of the preceding items, and a tour that emphasises the former while being vague about the latter has answered a question you did not ask.
Esketamine, marketed as Spravato, occupies a different regulatory position that is routinely blurred in advertising. It is the S-enantiomer of ketamine, delivered as a nasal spray, and the FDA approved it in 2019 for treatment-resistant depression in adults used alongside an oral antidepressant, then in 2020 for depressive symptoms in adults with major depressive disorder and acute suicidal ideation or behaviour. Because it carries a Risk Evaluation and Mitigation Strategy, it can only be given at certified treatment centres, the patient must be observed for at least two hours afterwards, and they cannot drive until the following day. That is the entire practical difference for most people: esketamine is approved, insurable more often than not, and inconvenient; generic intravenous ketamine is off-label, usually paid out of pocket, and more flexible in how it is dosed.
How this route compares with the alternatives
Approval for esketamine extends to depressive symptoms in adults with major depressive disorder and acute suicidal ideation, a narrow and specific indication rather than a general one. In 2023 the FDA warned publicly about compounded ketamine used at home without monitoring, citing sedation, dissociation and airway risk with no clinician present. It is the first thing to establish about any the United States programme. In the United States the same rule applies: commercial insurance seldom reimburses off-label intravenous administration, though the associated psychiatric evaluation is sometimes billable and worth asking about specifically. Any programme presenting six sessions as a complete and finished treatment, without discussing maintenance, has described half of what is involved.
Integration is the term the field uses for the work of making sense of what happened, and it is the element most likely to be missing from a purely procedural clinic. The neuroplasticity hypothesis implies that the days following a session may be unusually receptive to therapeutic change, which suggests that pairing sessions with structured psychological support is not an upsell but a plausible way to use the window. Programmes vary enormously in how seriously they take this: some employ therapists and build integration sessions into the protocol, others hand over a worksheet, and some do nothing at all. Asking directly what integration support is included, and whether it costs extra, separates the two models quickly.
Who this route suits and who it does not
The phrase treatment-resistant carries a specific meaning, and it only applies after documented trials at appropriate doses and durations. Uncontrolled hypertension is treated as a serious caution for a straightforward physiological reason, and a programme that does not check blood pressure before dosing has skipped a step. Anyone comparing the United States programmes will find this decisive: the honest summary is that the short-term findings are encouraging and the long-term picture remains genuinely unsettled.
It is worth pausing on the underlying medicine before returning to the United States. Screening is where a careful programme distinguishes itself, and it happens before anyone discusses scheduling. A thorough intake covers cardiovascular history, because of the blood pressure response; personal and family history of psychosis or bipolar disorder, because of the risk of precipitating an episode; hepatic function, because the liver metabolises the drug; substance use history; current medications and their interactions; and pregnancy status. It should also establish what has already been tried and at what dose, since the term treatment-resistant carries a specific meaning that only applies after adequate trials of at least two antidepressants. A consultation that skips most of this and moves quickly to a package price is telling you something about how the clinic is run.
Cost, coverage and the practical arithmetic
What this comes down to is that a single infusion in the United States commonly falls between four hundred and eight hundred dollars, putting a six-session induction somewhere near two and a half to five thousand. Applied to the United States, the point is this: solid food is usually restricted for several hours beforehand, largely to limit nausea during administration. Pairing sessions with structured psychological support follows directly from the mechanism, which makes its absence a substantive gap rather than a stylistic one. It is worth carrying that into every conversation with a the United States provider.
None of the United States detail on this page makes sense without the clinical context behind it. The mechanism is where ketamine departs from the antidepressants most people have already tried. Conventional selective serotonin reuptake inhibitors work primarily on monoamine systems and typically need four to six weeks before any effect is assessable. Ketamine acts on the glutamate system, principally as an antagonist at the N-methyl-D-aspartate receptor, and the downstream cascade it appears to trigger involves a surge in brain-derived neurotrophic factor and a measurable increase in synaptic connections in regions associated with mood regulation. Researchers describe this as a window of heightened neuroplasticity. The clinically useful framing is that ketamine may open a period during which the brain is more amenable to change, which is precisely why the therapeutic work done around the infusion matters as much as the infusion.
The practical checklist, written as prose
Taken at face value, search results for ketamine treatment in the United States return a remarkably uniform set of pages, which makes genuine comparison harder rather than easier. The logistics of an induction course are what quietly determine whether people finish treatment or abandon it partway through. Telehealth has a legitimate role here for consultation, screening, follow-up and integration therapy, and it materially improves access for people far from a metropolitan clinic. Patients researching the United States providers run into this constantly. Where the evidence is strongest concerns short courses in adults who have not responded to at least two adequate antidepressant trials.
Ketamine is a Schedule III controlled substance in the United States, and that legal status shapes the entire delivery landscape. It means the drug carries a recognised potential for misuse and dependence. Legitimate programmes respond to that with structural safeguards rather than reassurance: doses administered on site and observed, no take-home supply of injectable product, defined session intervals, and screening that takes substance use history seriously rather than treating it as a formality. A programme willing to escalate frequency on request, or to ship product without meaningful assessment, has removed the guardrails that make the risk manageable.
Weight-based dosing in the region of 0.5 milligrams per kilogram over roughly forty minutes is the convention, though clinics vary in whether they adjust it between sessions. That holds in the United States as it does everywhere: six infusions over roughly three weeks is the common induction pattern, though some programmes offer four and others extend to eight. The clinics that treat this as a psychiatric treatment rather than a procedure tend to build psychological support into the protocol rather than offering it as an upsell. The infusion can be slowed or stopped if someone becomes distressed, and knowing that in advance is itself a meaningful part of preparation.
Risks, contraindications and honest caution
Headache, dizziness and several hours of grogginess afterwards are ordinary, and driving is prohibited for the remainder of the day without exception. Whether a programme titrates the dose according to response and tolerability, or runs a fixed protocol for everyone, is a meaningful difference in how individualised the care actually is. The United States listings on this page are organised so that this is checkable rather than assumed. Ketamine work sits between psychiatric assessment and sedation management, and clinicians arrive at it from either side with correspondingly different instincts. That is as true in the United States as anywhere else in the country. Cost is the constraint that settles the question for a large share of people, which makes the reluctance to publish prices worth noticing.
In 2023 the FDA issued a public warning about compounded ketamine products used at home without monitoring, citing risks including sedation, dissociation, airway compromise and the absence of any clinician present if something goes wrong. That warning is the clearest available signal about where the regulatory line sits. Telehealth has a legitimate and useful role in this field for consultation, screening, follow-up and integration therapy, and it materially improves access for people far from a metropolitan clinic. Using it to mail a dissociative anaesthetic to an unmonitored patient is a different proposition, and the distinction is worth insisting on.
Read against the United States market, the practical difference is that esketamine is approved and more often insurable but less flexible, while intravenous ketamine is off-label, usually self-funded and more adjustable. For anyone weighing options in the United States, the induction course is the part everyone discusses; what happens after it is the part that determines the real cost and the real commitment. Coordination with an existing prescriber is a marker of considered practice, even though it slows the path to a first appointment. The trial evidence is real and also limited: studies tend to be small, follow-up periods short, and blinding is notoriously difficult when the dissociative effect is obvious to participants. Nothing about the United States changes that.
Choosing Esketamine nasal spray (Spravato) with clear eyes
Travel time belongs in the treatment plan rather than being treated as a detail to solve later. The difficulty facing someone comparing options in the United States is not a shortage of information but an excess of the promotional kind. Asking whether integration support is included, who provides it and whether it costs extra separates two quite different models of care within a single phone call. It is worth carrying that into every conversation with a the United States provider. Asking for an annualised cost rather than a per-session figure produces a far more useful number and occasionally a revealing pause. Whether a programme is led by someone trained in sedation or someone trained in mood disorders changes what gets emphasised and what gets assumed. It is the first thing to establish about any the United States programme.
None of this replaces a conversation with a clinician who knows your history. It is meant to make that conversation sharper, so that the appointment is spent on judgement rather than on establishing basic facts.
This page is general information, not medical advice, and no directory can assess whether a treatment is appropriate for an individual. Ketamine is a controlled substance with genuine risks, and its use for mood disorders is off-label apart from esketamine, which holds FDA approval for treatment-resistant depression under a restricted programme. Decisions about treatment should be made with a qualified clinician who knows your full history. If you are in crisis, contact the 988 Suicide and Crisis Lifeline by calling or texting 988 in the United States, or go to your nearest emergency department.